<?xml version="1.0" encoding="utf-8"?>
<feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom">
  <title
    type="text">Cleveland BioLabs, Inc.</title>
  <subtitle
    type="text">Contains the last 20 releases</subtitle>
  <id>uuid:3daf3459-5e5a-48fc-9be8-b490f50e4b4c;id=27176</id>
  <rights
    type="text">Copyright 2017, Cleveland BioLabs, Inc.</rights>
  <updated>2017-11-14T13:15:00Z</updated>
  <author>
    <name>newsdesk@globenewswire.com (NewsDesk)</name>
    <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri>
    <email>newsdesk@globenewswire.com</email>
  </author>
  <link
    rel="alternate"
    href="https://www.globenewswire.com/atomfeed/organization/z-3-QL_X9RkOYxUsazlITQ==" />
  <link
    rel="self"
    href="https://www.globenewswire.com/atomfeed/organization/z-3-QL_X9RkOYxUsazlITQ==" />
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/11/14/1230574/0/en/Cleveland-BioLabs-Reports-Third-Quarter-2017-Financial-Results-and-Development-Progress.html</id>
    <title
      type="text">Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress </title>
    <published>2017-11-14T13:15:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/11/14/1230574/0/en/Cleveland-BioLabs-Reports-Third-Quarter-2017-Financial-Results-and-Development-Progress.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Nov 14, 2017) - <strong>&#160;Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the third quarter ended September 30, 2017.</p>]]></content>
    <dc:identifier>1230574</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/08/14/1230570/0/en/Cleveland-BioLabs-Reports-Second-Quarter-2017-Financial-Results-and-Development-Progress.html</id>
    <title
      type="text">Cleveland BioLabs Reports Second Quarter 2017 Financial Results and Development Progress </title>
    <published>2017-08-14T12:12:09Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/08/14/1230570/0/en/Cleveland-BioLabs-Reports-Second-Quarter-2017-Financial-Results-and-Development-Progress.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Aug 14, 2017) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the second quarter ended June 30, 2017.</p>]]></content>
    <dc:identifier>1230570</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/05/15/1230565/0/en/Cleveland-BioLabs-Reports-First-Quarter-2017-Financial-Results-and-Development-Progress.html</id>
    <title
      type="text">Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress </title>
    <published>2017-05-15T11:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/05/15/1230565/0/en/Cleveland-BioLabs-Reports-First-Quarter-2017-Financial-Results-and-Development-Progress.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - May 15, 2017) -  <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the first quarter ended March 31, 2017. </p>]]></content>
    <dc:identifier>1230565</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/04/17/1230559/0/en/Cleveland-BioLabs-Announces-Commencement-of-In-Vivo-Biocomparability-Study.html</id>
    <title
      type="text">Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study </title>
    <published>2017-04-17T11:36:35Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/04/17/1230559/0/en/Cleveland-BioLabs-Announces-Commencement-of-In-Vivo-Biocomparability-Study.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Apr 17, 2017) - <strong>&#160;Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of a side-by-side analytical comparison of two formulations of entolimod. The FDA agreed with CBLI that these data indicate the <em>in vitro</em> analytical comparability of the formulations.&#160;Based on the outcome of its review, the FDA has provided CBLI with its consent for initiation of an <em>in vivo</em> biocomparability study of these formulations in non-human primates (NHP).</p>]]></content>
    <dc:identifier>1230559</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/04/17/1230562/0/en/Cleveland-BioLabs-Announces-European-Medicines-Agency-Positive-Opinion-Regarding-the-Entolimod-Pediatric-Investigation-Plan.html</id>
    <title
      type="text">Cleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan </title>
    <published>2017-04-17T11:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/04/17/1230562/0/en/Cleveland-BioLabs-Announces-European-Medicines-Agency-Positive-Opinion-Regarding-the-Entolimod-Pediatric-Investigation-Plan.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Apr 17, 2017) - <strong>&#160;Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the European Medicines Agency (EMA) has accepted the company's pediatric investigation plan (PIP), paving the way for submission of a Marketing Authorization Application (MAA) for entolimod as a medical radiation countermeasure. </p>]]></content>
    <dc:identifier>1230562</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/04/11/1230554/0/en/Cleveland-BioLabs-Announces-Webcast-of-Annual-Meeting.html</id>
    <title
      type="text">Cleveland BioLabs Announces Webcast of Annual Meeting </title>
    <published>2017-04-11T21:00:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/04/11/1230554/0/en/Cleveland-BioLabs-Announces-Webcast-of-Annual-Meeting.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Apr 11, 2017) - <strong>&#160;Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the Company will webcast its 2017 Annual Meeting of Stockholders on April 21, 2017 at its headquarters in Buffalo, NY. </p>]]></content>
    <dc:identifier>1230554</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/02/22/1230551/0/en/Cleveland-BioLabs-Reports-2016-Financial-Results-and-Development-Progress.html</id>
    <title
      type="text">Cleveland BioLabs Reports 2016 Financial Results and Development Progress </title>
    <published>2017-02-22T21:15:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/02/22/1230551/0/en/Cleveland-BioLabs-Reports-2016-Financial-Results-and-Development-Progress.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Feb 22, 2017) -  <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the fourth quarter and year ended December 31, 2016. </p>]]></content>
    <dc:identifier>1230551</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/11/14/1230546/0/en/Cleveland-BioLabs-Reports-Third-Quarter-2016-Financial-Results-and-Development-Progress.html</id>
    <title
      type="text">Cleveland BioLabs Reports Third Quarter 2016 Financial Results and Development Progress </title>
    <published>2016-11-14T12:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/11/14/1230546/0/en/Cleveland-BioLabs-Reports-Third-Quarter-2016-Financial-Results-and-Development-Progress.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Nov 14, 2016) - <strong>&#160;Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the third quarter ended September 30, 2016. </p>]]></content>
    <dc:identifier>1230546</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/10/11/1230543/0/en/Cleveland-BioLabs-Announces-a-1-1-Million-Cost-Realignment-With-the-Department-of-Defense.html</id>
    <title
      type="text">Cleveland BioLabs Announces a $1.1 Million Cost Realignment With the Department of Defense </title>
    <published>2016-10-11T12:45:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/10/11/1230543/0/en/Cleveland-BioLabs-Announces-a-1-1-Million-Cost-Realignment-With-the-Department-of-Defense.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Oct 11, 2016) -  <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the Department of Defense (DoD) has modified its Joint Warfighter Medical Research Program (JWMRP) contract award number W81XWH-15-C-0101 with CBLI valued at up to $9.2 million which supports further development of entolimod as a medical radiation countermeasure. </p>]]></content>
    <dc:identifier>1230543</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/08/15/1230542/0/en/Cleveland-BioLabs-Reports-Second-Quarter-2016-Financial-Results-and-Development-Progress.html</id>
    <title
      type="text">Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress </title>
    <published>2016-08-15T12:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/08/15/1230542/0/en/Cleveland-BioLabs-Reports-Second-Quarter-2016-Financial-Results-and-Development-Progress.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Aug 15, 2016) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the second quarter ended June 30, 2016. </p>]]></content>
    <dc:identifier>1230542</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/07/12/1230540/0/en/Cleveland-BioLabs-Announces-Board-Resignations.html</id>
    <title
      type="text">Cleveland BioLabs Announces Board Resignations </title>
    <published>2016-07-12T13:00:48Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/07/12/1230540/0/en/Cleveland-BioLabs-Announces-Board-Resignations.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Jul 12, 2016) -  <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that Board Chair Richard McGowan and Audit Committee Chair James Antal resigned from the company's Board of Directors, effective last Friday, July 8. Their resignations were predicated on the Board's decision not to renew its policy of directors' and officers' liability insurance as a cost-saving measure. CBLI will seek to fill these Board vacancies as soon as possible.</p>]]></content>
    <dc:identifier>1230540</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/05/16/1230537/0/en/Cleveland-BioLabs-Reports-First-Quarter-2016-Financial-Results-and-Development-Progress.html</id>
    <title
      type="text">Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress </title>
    <published>2016-05-16T11:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/05/16/1230537/0/en/Cleveland-BioLabs-Reports-First-Quarter-2016-Financial-Results-and-Development-Progress.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - May 16, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the first quarter ended March 31, 2016. </p>]]></content>
    <dc:identifier>1230537</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/04/04/1230535/0/en/Cleveland-BioLabs-Announces-Webcast-of-Annual-Meeting.html</id>
    <title
      type="text">Cleveland BioLabs Announces Webcast of Annual Meeting </title>
    <published>2016-04-04T11:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/04/04/1230535/0/en/Cleveland-BioLabs-Announces-Webcast-of-Annual-Meeting.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Apr 4, 2016) - <strong>&#160;Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the Company will webcast its 2016 Annual Meeting of Stockholders on April 14, 2016 at its headquarters in Buffalo, NY. </p>]]></content>
    <dc:identifier>1230535</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/03/16/1230532/0/en/Cleveland-BioLabs-Provides-Update-on-Pre-EUA-Review-of-Entolimod-as-Radiation-Countermeasure.html</id>
    <title
      type="text">Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure </title>
    <published>2016-03-16T18:00:06Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/03/16/1230532/0/en/Cleveland-BioLabs-Provides-Update-on-Pre-EUA-Review-of-Entolimod-as-Radiation-Countermeasure.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Mar 16, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced an update on the regulatory review of its pre-Emergency Use Authorization (pre-EUA) submission for entolimod as a radiation countermeasure following the receipt of minutes from a recent meeting with the U.S. Food and Drug Administration (FDA).</p>]]></content>
    <dc:identifier>1230532</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/02/22/1230530/0/en/Cleveland-BioLabs-Reports-2015-Financial-Results-and-Development-Progress.html</id>
    <title
      type="text">Cleveland BioLabs Reports 2015 Financial Results and Development Progress </title>
    <published>2016-02-22T12:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/02/22/1230530/0/en/Cleveland-BioLabs-Reports-2015-Financial-Results-and-Development-Progress.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Feb 22, 2016) -  <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the fourth quarter and year ended December 31, 2015. </p>]]></content>
    <dc:identifier>1230530</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/02/09/1230528/0/en/Entolimod-Shown-to-Suppress-Metastasis-and-Induce-Immunity-by-Stimulating-NK-Dendritic-CD8-T-cell-Axis-in-Studies-by-Cleveland-BioLabs-and-Roswell-Park-Cancer-Institute.html</id>
    <title
      type="text">Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute </title>
    <published>2016-02-09T12:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/02/09/1230528/0/en/Entolimod-Shown-to-Suppress-Metastasis-and-Induce-Immunity-by-Stimulating-NK-Dendritic-CD8-T-cell-Axis-in-Studies-by-Cleveland-BioLabs-and-Roswell-Park-Cancer-Institute.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Feb 9, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) and <strong>Roswell Park Cancer Institute (RPCI) </strong>today announced the publication of studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis.&#160;The data were published in <em>Proceedings of the National Academy of Sciences of the United States of America</em> (<em>PNAS),</em> the official journal of the United States National Academy of Sciences, based on studies conducted by scientists at RPCI and CBLI. </p>]]></content>
    <dc:identifier>1230528</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/02/02/1230525/0/en/Cleveland-BioLabs-Announces-Start-of-Colorectal-Cancer-Study-of-Entolimod-in-Russian-Federation.html</id>
    <title
      type="text">Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation </title>
    <published>2016-02-02T13:00:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/02/02/1230525/0/en/Cleveland-BioLabs-Announces-Start-of-Colorectal-Cancer-Study-of-Entolimod-in-Russian-Federation.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Feb 2, 2016) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-na&#239;ve patients with primary colorectal cancer who are recommended for surgery.&#160;</p>]]></content>
    <dc:identifier>1230525</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/01/26/1230523/0/en/Cleveland-BioLabs-Announces-Start-of-Phase-2-Study-of-CBLB612-in-Russian-Federation.html</id>
    <title
      type="text">Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation </title>
    <published>2016-01-26T12:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/01/26/1230523/0/en/Cleveland-BioLabs-Announces-Start-of-Phase-2-Study-of-CBLB612-in-Russian-Federation.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Jan 26, 2016) - <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy.</p>]]></content>
    <dc:identifier>1230523</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/01/21/1230521/0/en/Cleveland-BioLabs-Attains-Orphan-Drug-Status-From-the-EMA-for-Entolimod-as-a-Radiation-Countermeasure.html</id>
    <title
      type="text">Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure </title>
    <published>2016-01-21T12:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/01/21/1230521/0/en/Cleveland-BioLabs-Attains-Orphan-Drug-Status-From-the-EMA-for-Entolimod-as-a-Radiation-Countermeasure.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Jan 21, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for treatment of acute radiation syndrome.&#160;Acute radiation syndrome comprises serious bone marrow, gastrointestinal, and other toxicities arising from exposure to high doses of radiation. </p>]]></content>
    <dc:identifier>1230521</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2015/12/22/1230519/0/en/Cleveland-BioLabs-and-Rusnano-Make-Additional-Investments-in-Panacela.html</id>
    <title
      type="text">Cleveland BioLabs and Rusnano Make Additional Investments in Panacela </title>
    <published>2015-12-22T12:30:00Z</published>
    <updated>2024-12-03T02:57:11Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2015/12/22/1230519/0/en/Cleveland-BioLabs-and-Rusnano-Make-Additional-Investments-in-Panacela.html" />
    <content
      type="html"><![CDATA[<p>BUFFALO, NY--(Marketwired - Dec 22, 2015) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that through a series of transactions and in cooperation with Open Joint Stock Company RUSNANO (Rusnano) it has recapitalized Panacela Labs, Inc. (Panacela), a majority-owned joint venture.&#160;</p>]]></content>
    <dc:identifier>1230519</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor>
    <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified>
  </entry>
</feed>